Table 2.
Diagnostic characteristics of Guideline-Based Statin Eligibility for CCTA-Detected CAD
| Sensitivity | Specificity | PPV | NPV | Balanced Accuracy* | |
|---|---|---|---|---|---|
| 2004 ATP III | 27.3 (18.3–37.8) |
83.2 (74.4–89.9) |
58.5 (42.1–73.7) |
56.8 (48.4–64.9) |
55.2 (49.3–61.2) |
|
2013 ACC/AHA (7.5%) |
53.4 (42.5–64.1) |
70.3 (60.4–79.0) |
61.0 (49.2–72.0) |
63.4 (53.8–72.3) |
61.9 (55.0–68.7) |
|
2013 ACC/AHA (5%) |
71.6 (61.0–80.7) |
61.4 (51.2–70.9) |
61.8 (51.6–71.2) |
71.3 (60.6–80.5) |
66.5 (59.8–73.2) |
| 2011 European | 34.1 (24.3–45.0) |
86.1 (77.8–92.2) |
68.2 (52.4–81.4) |
60.0 (51.5–68.0) |
60.1 (54.1–66.1) |
95% Confidence Intervals are in brackets;
*
Balanced Accuracy = Area under the receiver operating characteristic curve = (Sensitivity + Specificity)/2